About Comparative Biosciences
Comparative Biosciences is a Healthcare company based in Sunnyvale (United States) founded in 1996, and was acquired by Genesis Biotechnology Group in August 2020. Provider of preclincial services specializing in studies involving stem cell, diabetes and cancer therapies. Comparative Biosciences offers products and services including Toxicology Services, Pharmacokinetics Services, and Histopathology Services. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its legal entity is COMPARATIVE BIOSCIENCES, INC. Its competitors include BioQual, ReveraGen and Headlands Research.
Company details
Founded in 1996 and based in Sunnyvale, United States, Comparative Biosciences operates as a contract research organization focused on GLP and non-GLP preclinical studies. Services encompass toxicology, efficacy, pharmacology, PKPD, histopathology, and safety assessments across laboratory species. Expertise covers therapeutic areas including oncology, ophthalmology, cardiovascular, and immune-mediated models, with custom development and contract histopathology offered. AAALAC accreditation is maintained, and clients include biomedical firms, pharmaceutical companies, academia, and government entities.
- Headquarters Sunnyvale, United States
- Stage Acquired
- SectorsHealthcare
- Website compbio.com
- Social LinkedIn YouTube
- Acquired by Genesis Biotechnology Group (Aug 2020)
- Legal Name Comparative Biosciences, Inc.
- Investors
- Acquired byGenesis Biotechnology Group
(Aug 2020)
Products & Services of Comparative Biosciences
Comparative Biosciences offers a comprehensive portfolio of products and services, including Toxicology Services, Pharmacokinetics Services, and Histopathology Services.
Conducts toxicology studies in rodents for safety assessment
Evaluates drug absorption and distribution in preclinical models
Performs tissue analysis for research and regulatory purposes
Apps and channels of Comparative Biosciences
its YouTube channel K. David Katzmire has 33 subscribers and 12 videos.
Videos from Comparative Biosciences
The most watched videos on Comparative Biosciences's YouTube channel, K. David Katzmire (33 subscribers). Click a video to play it here.
More on K. David Katzmire.
Investors in Comparative Biosciences
Comparative Biosciences has secured backing from 1 investor. Prominent investors backing the company include Genesis Drug Discovery & Development.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A contract research organization focused on drug discovery and development. | gd3services.com | Hamilton, United States |
Investor details for Comparative Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Comparative Biosciences
2 dated milestones of Comparative Biosciences across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Comparative Biosciences is founded.
- Exit Acquired by Genesis Biotechnology Group.
Competitors of Comparative Biosciences
Comparative Biosciences has 3 listed competitors in our database. They include BioQual, ReveraGen and Headlands Research.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bioqual.com | 1981 | Rockville, United States | 193 | Contract research on infectious disease models is conducted. | ||
| reveragen.com | 2008 | Rockville, United States | Steroids for Duchenne muscular dystrophy treatment are developed. | |||
| headlandsresearch.com | 2018 | San Francisco, United States | Clinical research services are provided by Headlands Research globally. |
Detailed competitors of Comparative Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Comparative Biosciences
Websites that share an audience with Comparative Biosciences (compbio.com).
Websites whose visitors overlap most with Comparative Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gwathmey.com | gwathmey.com | 100% | – | ||
| eyecro.com | 99% | 1.9K | #10,504,025 | View details | |
sneezetoronto.com | sneezetoronto.com | 96% | – | ||
| pharmamedica.com | 96% | 38.8K | #1,016,733 | View details | |
researchamerica.org | researchamerica.org | 76% | #1,819,679 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Comparative Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Comparative Biosciences (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Comparative Biosciences
Complete news archive for Comparative Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Comparative Biosciences
Comparative Biosciences was founded in 1996.
Comparative Biosciences is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Founded in 1996 and based in Sunnyvale, United States, Comparative Biosciences operates as a contract research organization focused on GLP and non-GLP preclinical studies. Services encompass toxicology, efficacy, pharmacology, PKPD, histopathology, and safety assessments across laboratory species. Expertise covers therapeutic areas including oncology, ophthalmology, cardiovascular, and immune-mediated models, with custom development and contract histopathology offered. AAALAC accreditation is maintained, and clients include biomedical firms, pharmaceutical companies, academia, and government entities.
Comparative Biosciences's top competitors include BioQual, ReveraGen and Headlands Research.
Comparative Biosciences offers Toxicology Services, Pharmacokinetics Services, and Histopathology Services.
Comparative Biosciences has 1 investor. Key investors include Genesis Drug Discovery & Development.
Comparative Biosciences operates through Comparative Biosciences, Inc..
Yes. Comparative Biosciences was acquired by Genesis Biotechnology Group in August 2020.